期刊
ONCOIMMUNOLOGY
卷 3, 期 7, 页码 -出版社
LANDES BIOSCIENCE
DOI: 10.4161/21624011.2014.944054
关键词
chemotherapy; glioblastoma; lymphopenia; immunotherapy; temozolomide
First- line chemotherapy to combat primary malignant brain cancer is often accompanied by lymphopenic immunologic deficiency. Although counterintuitive, chemotherapy-induced lymphopenia can provide excellent host conditioning that may actually be leveraged to potentiate antitumor immunotherapy. We discuss here our preclinical and clinical experiences applying immunotherapy against glioblastoma, the most common and lethal primary malignant brain tumor, as well as the use of immunotherapeutics in the setting of standard-of-care temozolomide chemotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据